LaurenceJ. “The path that ends AIDS:” National and international politics in conflict with treatment and prevention science. AIDS Patient Care STDS, 2023; 37(11):505–506.
2.
LaurenceJ. Intersecting pandemics of epidemiology, inequality, genetics, and immunology: COVID-19 and AIDS. AIDS Patient Care STDS, 2022; 36(5):169–171.
BekkerL-G, DasQ, KarimQA, et al.PURPOSE 1 Study Team. Twice-yearly lenacapavir or daily F/TAF for HIV prevention in cisgender women. N Engl J Med, 2024; doi: 10.1056/NEJMoa2407001
5.
GriffinDWJ, HoyJF, McMahonJH. Long-acting cabotegravir PrEP: A time for cautious optimism. Lancet HIV, 2023; 10(12):e756–e757.
6.
BeyrerC, TomarasGD, GelderblomHC, et al.Is HIV epidemic control by 2030 realistic? Lancet HIV, 2024; 11(7):e489–e494.